Papulopustular Rosacea Clinical Trial
Official title:
A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea
NCT number | NCT01784133 |
Other study ID # | CLS001-CO-PR-001 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | February 1, 2013 |
Last updated | May 1, 2015 |
Start date | March 2013 |
Verified date | May 2015 |
Source | Cutanea Life Sciences, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to evaluate th safety and efficacy of one-daily topical application of CLS001 low, mid and high dose compared to vehicle gel in subjects with papulopustular rosacea.
Status | Completed |
Enrollment | 240 |
Est. completion date | |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - diagnosis of papulopustular rosacea (at least 15 lesions) Exclusion Criteria: - nodular rosacea or subtype 3 - clinically significant abnormal findings that would interfere with study objectives |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Radiant Research Inc. | Birmingham | Alabama |
United States | Skin Care Research, Inc | Boca Raton | Florida |
United States | Dunedin Research Specialists | Dunedin | Florida |
United States | Dawes Fretzin Clinical Research Group | Indianapolis | Indiana |
United States | North Florida Dermatology Associates | Jacksonville | Florida |
United States | TriCities Skin and Cancer | Johnson City | Tennessee |
United States | Tennessee Clinical Research Center | Nashville | Tennessee |
United States | The Savin Center, PC | New Haven | Connecticut |
United States | Virginia Clinical Research Inc. | Norfolk | Virginia |
United States | Oregon Dermatology and Research Center | Portland | Oregon |
United States | Wake Resarch | Raleigh | North Carolina |
United States | Rochester General Medical Group Center for Dermatology at Linden Oaks | Rochester | New York |
United States | Dermatology Research Center | Salt Lake City | Utah |
United States | Progressive Clinical Research, PA | San Antonio | Texas |
United States | ATS Clinical Research | Santa Monica | California |
United States | Derm Research Center of NY Inc. | Stoney Brook | New York |
United States | Grekin Skin Institute | Warren | Michigan |
Lead Sponsor | Collaborator |
---|---|
Cutanea Life Sciences, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in inflammatory lesion count | 0, 1, 3, 6, 9 and 12 weeks | No | |
Secondary | Success on IGA defined as clear or almost clear | Week 12 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03276936 -
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
|
Phase 3 | |
Completed |
NCT02601963 -
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT02268474 -
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
|
N/A | |
Completed |
NCT01555463 -
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
|
Phase 3 | |
Active, not recruiting |
NCT03667222 -
Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
|
Phase 2 | |
Terminated |
NCT03564145 -
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
|
Phase 3 | |
Completed |
NCT05150587 -
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT03263273 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT05343455 -
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
|
Phase 3 | |
Completed |
NCT01872715 -
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
|
Phase 4 | |
Completed |
NCT05296629 -
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
|
Phase 3 | |
Completed |
NCT05838170 -
Study of TP-04 in Participants With Papulopustular Rosacea
|
Phase 2 | |
Recruiting |
NCT06013371 -
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
|
Phase 2 | |
Recruiting |
NCT03864978 -
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
|
Phase 2 | |
Completed |
NCT03564119 -
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
|
Phase 3 | |
Completed |
NCT03079531 -
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
|
Phase 1/Phase 2 | |
Completed |
NCT01045551 -
Open Label Pilot Study of Apremilast in Treatment of Rosacea
|
Phase 2 | |
Completed |
NCT03448939 -
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
|
Phase 3 | |
Completed |
NCT05675501 -
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
|
Phase 1 | |
Withdrawn |
NCT03883945 -
A Safety and Efficacy Study to Evaluate Rosacea
|
Phase 1/Phase 2 |